XLO XILIO THERAPEUTICS INC

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50 am EST.

A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at . A replay of the webcast will be archived on the website for 30 days following the presentation.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting  and follow us on LinkedIn (Xilio Therapeutics, Inc.).

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Investor and Media Contact

Scott Young

Vice President, Investor Relations and Corporate Communications



EN
24/02/2025

Underlying

XLOXILIO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on XILIO THERAPEUTICS INC

 PRESS RELEASE
Free
XLO XILIO THERAPEUT...

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants proportionately to the amount of non-dilutive capital received, under certain circumstances Financing co-led by new investors Coastlands Capital and Frazier Life Sciences and included participation from Gilead Sciences, Inc., Logos Capital, Samsara BioCapital and other new and existing investors WALTHAM, Mass., June ...

June 5, 2025 1 EN
 PRESS RELEASE
Free
XLO XILIO THERAPEUT...

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Ru...

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective June 1, 2025, the company granted non-qualified stock options to purchase 181,300 shares of its common stock to five new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $1.07 per ...

June 3, 2025 1 EN
 PRESS RELEASE
Free
XLO XILIO THERAPEUT...

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the pricing of an underwritten public offering of pre-funded warrants to purchase 66,676,000 shares of common stock (the “pre-funded warrants”), accompanied by Series A warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the...

June 2, 2025 1 EN
 PRESS RELEASE
Free
XLO XILIO THERAPEUT...

Xilio Therapeutics Announces Proposed Public Offering

Xilio Therapeutics Announces Proposed Public Offering WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it is commencing an underwritten public offering of pre-funded warrants to purchase shares of common stock accompanied by Series A warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants), Series B warrants to purchase shares of common stock (or, in ce...

June 2, 2025 1 EN
 PRESS RELEASE
Free
XLO XILIO THERAPEUT...

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a T...

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer 26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ongoing for up to 37 weeks through the data cutoff, accompanied by substantial decreases in tumor biomarkers and improvements in clinical symptoms MSS CRC patient with liver metastasis and prev...

May 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch